NetworkNewsBreaks – Predictive Oncology Inc. (NA
Post# of 281

Predictive Oncology (NASDAQ: POAI), a knowledge-driven company focused on applying artificial intelligence (“AI”) to personalized medicine and drug discovery, today announced its entry into definitive agreements with several institutional and accredited investors for the issuance and sale of an aggregate of 1,396,826 shares of its common stock. According to the update, the shares are each $1.575, in a registered direct offering priced at-the-market under Nasdaq rules, for gross proceeds of approximately $2.2 million. In addition, Predictive Oncology has agreed to issue to the investors unregistered warrants to purchase up to an aggregate of 1,396,826 shares of common stock. Subject to the satisfaction of customary conditions, the closing of the offering is expected to occur on or about May 8, 2020.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer

